Zimigut 550 Tablet contains Rifaximin 550 mg, a broad-spectrum, non-absorbable antibiotic primarily used to treat gastrointestinal infections. Rifaximin acts by inhibiting bacterial RNA synthesis, effectively targeting a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria within the gastrointestinal tract. Due to its minimal systemic absorption, Zimigut 550 is particularly effective in managing conditions localized to the gut, such as travelers’ diarrhea caused by non-invasive strains of Escherichia coli, hepatic encephalopathy by reducing ammonia-producing gut bacteria, and irritable bowel syndrome with diarrhea (IBS-D). The tablet is typically administered orally, with dosage and duration depending on the specific indication and patient condition. Zimigut 550 is generally well-tolerated, with a low incidence of systemic side effects due to limited systemic exposure. Common adverse effects may include nausea, abdominal pain, and flatulence. It is contraindicated in patients with known hypersensitivity to rifaximin or any component of the formulation. Caution is advised in patients with severe hepatic impairment. As with all antibiotics, appropriate use is essential to minimize the development of bacterial resistance. Zimigut 550 should be used under medical supervision to ensure optimal therapeutic outcomes.